Observational Study of Clinical Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer Patients Treated with Amivantamab-Containing Regimens Under Routine Clinical Practice

What this Trial Is About

Researchers are studying the outcomes of treatments containing amivantamab for people with advanced non-small cell lung cancer NSCLC that have specific mutations in the epidermal growth factor receptor EGFR gene. This research focuses on patients with common EGFR mutations, including exon 19 deletions or exon 21 L858R substitutions, to understand how these regimens perform in real-world medical practice. The study aims to capture clinical and health-related results for this serious lung cancer type, particularly when it has spread to other parts of the body. The study observes two groups of participants receiving amivantamab-based treatments as part of their standard care. One group includes patients treated with amivantamab combined with carboplatin and pemetrexed after previous therapy has failed. The other group involves participants receiving amivantamab with lazertinib as their first-line therapy. No study drugs are provided instead, researchers collect data from routine clinical visits, tracking how patients are treated according to usual medical practice. Participants are monitored for up to about 60 months to gather information on how long they continue treatment, progression-free survival, overall survival, and time to next treatment. Researchers also record adverse events, dose changes, use of other medications, and quality of life using specific questionnaires. This long-term observation helps to understand treatment impact and safety in everyday clinical settings without additional interventions or procedures beyond standard care.

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting